Immunomodulatory and Immunoadsorptive Treatments

Heart Failure Clinics

Volumn 1, Issue 3, 2005, Pages 457-465

  Staudt, Alexander ^a   Felix, Stephan B ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE ANTIBODY; CYTOKINE RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; PLACEBO; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VIRUS RNA;

ANTIBODY TITER; CELLULAR IMMUNITY; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; ECHOCARDIOGRAPHY; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOADSORPTION; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; MYOCARDITIS; NONHUMAN; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS GENOME;

ANIMALS; CARDIOMYOPATHY, DILATED; HUMANS; IMMUNOGLOBULINS; IMMUNOSORBENT TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MYOCARDITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645963479     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2005.06.008     Document Type: Review

References (51)

1. Smith S.C., and Allen P.M. Myosin-induced acute myocarditis is a T-cell mediated disease. J Immunol 147 (1991) 2141-2147
2. Schwimmbeck P.L., Badorff C., Schultheiss H.P., et al. Transfer of human myocarditis into severe combined immunodeficiency mice. Circ Res 75 (1994) 156-164
3. Klappacher G., Mundigler G., Papousek A., et al. Elevated circulating levels of beta-2 microglobulin in patients with idiopathic cardiomyopathy. Am J Cardiol 71 (1993) 119-122
4. Limas C.J., Goldenberg I.F., and Limas C. Soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy: correlation with disease severity and cardiac autoantibodies. Circulation 91 (1995) 631-634
5. Schulze K., Becker B.F., Schauer R., et al. Antibodies to ADP-ATP carrier: an autoantigen in myocarditis and dilated cardiomyopathy impair cardiac function. Circulation 81 (1990) 959-969
6. Caforio A.L., Grazzini M., Mann J.M., et al. Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 85 (1992) 1734-1742
7. Limas C.J., Goldenberg I.F., and Limas C. Autoantibodies against beta-adrenoceptors in human idiopathic dilated cardiomyopathy. Circ Res 64 (1989) 97-103
8. Magnusson Y., Wallukat G., Waagstein F., et al. Autoimmunity in idiopathic dilated cardiomyopathy: characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect. Circulation 89 (1994) 2760-2767
9. Fu L.X., Magnusson Y., Bergh C.H., et al. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 91 (1993) 1964-1968
10. Schultheiss H.P., Kuhl U., Janda I., et al. Antibody-mediated enhancement of calcium permeability in cardiac myocytes. J Exp Med 168 (1988) 2102-2119
11. Matsui S., Fu M.L.X., Katsuda S., et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol 29 (1997) 641-655
12. Jahns R., Boivin V., Hein L., et al. Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 113 (2004) 1419-1429
13. Nishimura H., Okazaki T., Tanaka Y., et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291 (2001) 319-322
14. Okazaki T., Tanaka Y., Nishio R., et al. Autoantibodies against troponin-I are responsible for dilated cardiomyopathy in PD-1 deficient mice. Nat Med 9 (2003) 1477-1483
15. Baba A., Yoshikawa T., and Ogawa S. Autoantibodies produced against sarcolemmal Na-K-ATPase: possible upstream targets of arrhythmias and sudden death in patients with dilated cardiomyopathy. J Am Coll Cardiol 40 (2002) 1153-1159
16. Nohria A., Lewis E., and Stevenson L.W. Medical management of advanced heart failure. JAMA 287 (2002) 628-640
17. Matsumori A., Yamada T., Suzuki H., et al. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 72 (1994) 561-566
18. Torre-Amione G., Kapadia S., Lee J., et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93 (1996) 704-711
19. Ferrari R., Bachetti T., Confortini R., et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 92 (1995) 1479-1486
20. Torre-Amione G., Kapadia S., Benedict C., et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 27 (1996) 1201-1206
21. Seta Y., Shan K., Bozkurt B., et al. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 2 (1996) 243-249
22. Francis S.E., Holden H., Holt C.M., et al. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol 30 (1998) 215-223
23. Bozkurt B., Kribbs S.B., Clubb Jr. F., et al. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97 (1998) 1382-1391
24. Kubota T., McTiernan C.F., Frye C.S., et al. Dilated cardiomyopathy in transgenic mice with cardiac specific overexpression of tumor necrosis factor-α. Circ Res 81 (1997) 627-635
25. Deswal A., Bozkurt B., Seta Y., et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 99 (1999) 3224-3226
26. Bozkurt B., Torre-Amione G., Warren M.S., et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (enbrel) in patients with advanced heart failure. Circulation 103 (2001) 1044-1047
27. Mann D.L., McMurray J.J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
28. Parrillo J.E., Cunnion R.E., Epstein S.E., et al. A prospective randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 321 (1989) 1061-1068
29. Mason J.W., O'Connell J.B., Herskowitz A., et al. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 333 (1995) 269-275
30. Wojnicz R., Nowalany-Kozielska E., Wojciechowska C., et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 104 (2001) 39-45
31. Frustaci A., Chimenti C., Calabrese F., et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 107 (2003) 857-863
32. Bowles N.E., Richardson P.J., Olson E.G., et al. Detection of coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet 17 (1986) 1120-1123
33. Kandolf R., Ameis D., Kirschner P., et al. In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: an approach to the diagnosis of viral heart disease. Proc Natl Acad Sci U S A 84 (1987) 6272-6276
34. Jin O., Sole M.J., Butany J.W., et al. Detection of enterovirus RNA in myocardial biopsies from patients with myocarditis and cardiomyopathy using gene amplification by polymerase chain reaction. Circulation 82 (1990) 8-16
35. Pauschinger M., Bowles N.E., Fuentes-Garcia F.J., et al. Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation 99 (1999) 1348-1354
36. Kuhl U., Pauschinger M., Schwimmbeck P.L., et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107 (2003) 2793-2798
37. Dwyer J. Manipulating the immune system with immune globulin. N Engl J Med 326 (1992) 107-116
38. Godeau B., Lesage S., Divine M., et al. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 82 (1993) 1415-1421
39. Arsura E., Bick A., Brunner N., et al. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 146 (1986) 1365-1368
40. Gullestad L., Aass H., Fjeld J.G., et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 103 2 (2001) 220-225
41. McNamara D.M., Holubkov R., Starling R.C., et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 103 (2001) 2254-2259
42. Dorffel W.V., Felix S.B., Wallukat G., et al. Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation 95 (1997) 1994-1997
43. Felix S.B., Staudt A., Dorffel W.V., et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol 35 (2000) 1590-1598
44. Muller J., Wallukat G., Dandel M., et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 101 (2000) 385-391
45. Felix S.B., Staudt A., Landsberger M., et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 39 (2002) 646-652
46. Staudt A., Staudt Y., Dörr M., et al. Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy. J Am Coll Cardiol 44 (2004) 829-836
47. Staudt A., Schaper F., Stangl V., et al. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation 103 (2001) 2681-2686
48. Bruggemann M., Williams G.T., Bindon C.I., et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 166 (1987) 1351-1361
49. Zwaka T.P., Manolov D., Ozdemir C., et al. Complement and dilated cardiomyopathy: a role of sublytic terminal complement complex-induced tumor necrosis factor-alpha synthesis in cardiac myocytes. Am J Pathol 161 (2002) 449-457
50. Staudt A., Böhm M., Knebel F., et al. Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients suffering from dilated cardiomyopathy. Circulation 106 (2002) 2448-2453
51. Staudt A., Dorr M., Staudt Y., et al. Role of immunoglobulin G-3 subclass in dilated cardiomyopathy-results from protein-A immunoadsorption. Am Heart J, in press